Filing Flows › Lenz Therapeutics (LENZ) › Q3 2026
Lenz Therapeutics (LENZ) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 3, 2026
Lenz Therapeutics (LENZ) reported revenue of $3.4M for the third quarter 2026 (Q3 2026), -73% from a year earlier and -38% from the quarter before. Operating margin was -972.8%, net loss $31.0M (915.2% of revenue).
Lenz Therapeutics, Q3 2026: revenue $3.4M (-73% year over year), operating margin -972.8%, net loss $31.0M, operating cash flow −$22.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.4M | -38% | -73% |
| Operating profit | −$32.9M | — | — |
| Net earnings | −$31.0M | — | — |
| Operating cash flow | −$22.3M | — | — |
What changed
Revenue was $3.4M in Q3 2026, down 73% year over year and down 38% from the previous quarter. Product sales, net was the largest line at 77% of revenue. License revenue lost $11.7M year over year (down 94%), 129% of the total change.
Operating costs exceeded revenue by $32.9M, an operating margin of -972.8%. Total costs grew 16% against a revenue fall of 73%. The fastest-growing cost line was SG&A (+30%). The quarter ended with a net loss of $31.0M, narrower than the previous quarter's $31.9M loss.
Operating cash flow was −$22.3M. Non-cash charges added back $109K of depreciation and amortization and $4.1M of share-based compensation. Working capital and other items added $4.4M.
Questions
What was Lenz Therapeutics' revenue in the third quarter 2026?
Lenz Therapeutics (LENZ) reported revenue of $3.4M for the third quarter 2026 (Q3 2026), -73% from a year earlier and -38% from the quarter before.
Was Lenz Therapeutics profitable in the third quarter 2026?
Operating loss was $32.9M (-972.8% of revenue) and net loss $31.0M.
Source: Lenz Therapeutics 10-Q on SEC EDGAR.